Research programme: CAR-T regulatory cell therapy - AstraZeneca/Quell Therapeutics
Alternative Names: CAR-Treg cell therapy - Quell Therapeutics/AstraZenecaLatest Information Update: 30 Jun 2023
At a glance
- Originator Quell Therapeutics
- Developer AstraZeneca; Quell Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Inflammatory bowel diseases; Type 1 diabetes mellitus
Most Recent Events
- 09 Jun 2023 Quell Therapeutics and AstraZeneca entered into a collaboration, exclusive option and license agreement for CAR-T regulatory cell therapy in Type 1 diabetes mellitus and Inflammatory bowel diseases
- 09 Jun 2023 Early research in Inflammatory bowel diseases in United Kingdom (Parenteral)
- 09 Jun 2023 Early research in Type 1 diabetes mellitus in United Kingdom (Parenteral)